Published • loading... • Updated
NHS Rolls Out Faster Keytruda Jab for 14 Cancers
The ready-to-use shot could save more than 100,000 clinical hours a year and let thousands of patients spend less time in hospital, NHS England said.
- The NHS has begun rolling out a one-minute injectable immunotherapy for more than a dozen cancers, with early patients including 89-year-old Shirley Xerxes receiving treatment at Mount Vernon Cancer Centre in Hertfordshire.
- Previously, immunotherapy treatment required IV drips lasting up to 45 minutes using about 100mls of fluid; the new formulation slashes administration time by up to 90% and cuts staff preparation time by 44%.
- Around 14,000 patients start Pembrolizumab therapy annually in England, with most expected to switch to injections given every three or six weeks depending on cancer type.
- Professor Peter Johnson, NHS national clinical director for cancer, called the immunotherapy a "lifeline for thousands of patients," while Health and Social Care Secretary Wes Streeting said it offers "quicker, more convenient care."
- Reducing treatment time frees up vital appointments for NHS teams, enabling them to treat more patients and continue bringing down waiting times across oncology services.
Insights by Ground AI
29 Articles
29 Articles
The NHS Just Changed Cancer Care Forever With a 1-Minute Injection
The NHS has begun rolling out a new form of cancer immunotherapy that allows patients to receive treatment in as little as one minute, marking a significant shift in how some of the most widely used cancer drugs are administered across England. The injection, a subcutaneous version of pembrolizumab (Keytruda), replaces the traditional intravenous drip that can take between 30 minutes and two hours. According to NHS England, the new approach can …
·United Kingdom
Read Full Article
Coverage Details
Total News Sources29
Leaning Left7Leaning Right2Center9Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 39%
C 50%
11%
Factuality
To view factuality data please Upgrade to Premium
